Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide

Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram…. Journal of Medicinal Chemistry 2015

Document identifier
CEI-BR-063
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T
Title
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Source
Journal of Medicinal Chemistry
Year
2015
Volume, issue, pages
58(18):7370–7380
Digital object identifier
10.1021/acs.jmedchem.5b00726
PubMed identifier
26308095
Record type
Journal article
Institute identifier
CEI-BR-063

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

§1.3Subject tags

semaglutide chemistry structure

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.